शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
THEMISMEDBSETHEMIS MEDICARE LTD.· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Fri, 30 Oct, 2026 · 10:44 IST

Encumbered Themis holding rises to 35.09% after 4 million additional shares pledged

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.8%Reaction day
₹97.89
prior close
₹97.98
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-2.5%-1.3% vs market
Pharmaceuticals peers, median of 173sector-0.8%-3.0% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.9
15m
+0.7
30m
+0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.8-2.5-1.3-0.8-3.0
Next day
+3.4-1.1+4.5-0.8+4.2
2d
+2.0-0.8+2.8-0.5+2.5
3d
+2.0+1.3+0.6+0.3+1.6
4d
+4.1pendingpending+1.3+2.8
5d
+2.7pendingpending+1.3+1.4
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CTL Trusteeship, acting as debenture trustee for OSS Software Solutions Labs, disclosed two additional pledges by Vividhmargi Trust: 1.5 million Themis shares on October 22, 2026 and 2.5 million on October 27. Encumbered holding rose from 28,317,620 shares, or 30.75%, to 32,317,620 shares, or 35.09%. No voting rights or new shares were created.

Likely market impact

No change in ownership, voting control or share capital. The larger pledge increases collateral and potential enforcement risk for shareholders.